eClinical Software: April 2009
Applied Clinical Trials
The latest eclinical software in the clinical trials industry.
CTMS Integrates Data for Efficiencies
Product includes claims data for site identification
i3 Global (Basking Ridge, NJ) announced its Web-based, clinical trial and data management system i3Cube. i3Cube offers additional data mining into health care claims data to help users target investigators with appropriate patient populations, as well as determine the sites and patients that best match protocol criteria for studies.
Other product benefits include intuitive user interface, customized reporting, automated workflow, collaborative communication portal, single document repository, and informative dashboards. These dashboards summarize all clinical trial information at a high level, with drill down for specifics. Access rights to the clinical trial information are determined by role, i.e., CRA, project manager.
i3 Global, (866) 306-1296, www.i3global.com
Small to Midsize Business Needs Addressed
Hosted solution manages, analyzes, reviews clinical trials data
SAS (Cary, NC) announces its Solution OnDemand: Drug Development for the small to midsize businesses that help review clinical trials data in order to determine safety and efficacy outcomes. The Web-based hosted solution aggregates, analyzes, and reviews clinical trials data. The solution also includes a compliance-enabling platform for developing, executing, and managing the collection, sharing, transformation, analysis, and submission of clinical research data.
This application basically addresses limited IT infrastructure and resources of smaller companies. It features secure access for internal and external user communities, which can include CROs, collaborative development partners, and monitoring committees. Also, as a hosted solution, there are no direct hardware or software installation, systems administration, validation or maintenance costs.
SAS, (919) 677-8000, www.sas.com
Social Networking for Clinical Research Patients
Application addresses both recruitment and clinical trial awareness
Acurian, Inc. (Horsham, PA) announces its new social networking application Click it Forward. The company developed the application for the two most popular social networking platforms, Facebook and MySpace.
People register and install the free Click it Forward application on their Facebook or MySpace page and then spread the application exponentially by inviting online friends to install it. The user then gains points, which translates into the amount of money Acurian will donate to the preferred medical causes the user selects. The application also integrates Google Earth so users can see a visual map of their own Click it Forward network.
Acurian, Inc., (866) 566-5966, www.acurian.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
